arrow
S

Suzanne Kosmider

Western Health
H指数:23
被引数:5,002

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PP01.58: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) in Combination with Chemotherapy in First-Line (1L) Non-Small Cell Lung Cancer (NSCLC) – ROSETTA Lung-02

PP01.58:一项全球性II/III期、随机、开放标签试验,评估Pumitamig(BNT327/BMS986545;PD-L1 × VEGF-A 双特异性抗体)联合化疗在一线(1L)非小细胞肺癌(NSCLC)中的疗效——ROSETTA Lung-02

2026-05-070
PRE
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer

探索一线EGFR抑制剂使用、西妥昔单抗与帕尼单抗在左侧RAS野生型转移性结直肠癌患者中的真实世界结局

2025-04-300
PRE
Initial Assessment of Resectability of Colorectal Cancer Liver Metastases Versus Clinical Outcome

结直肠癌肝转移可切除性与临床结局的初步评估

2025-03-010
PRE
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

循环肿瘤DNA分析指导 ⅱ 期结肠癌的辅助治疗

2022-06-16440
OA
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

结直肠癌肝转移根治性切除患者循环肿瘤DNA动态和复发风险: 一项前瞻性队列研究

2021-05-03110
OAAI
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status

表现状态差或非常差的转移性结直肠癌患者的真实世界治疗和结果

2021-03-017
PREAI
Prognostic significance of postsurgery circulating tumorDNAin nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
2020-10-0690
OAAI
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry

贝伐单抗和晚期抗表皮生长因子受体抗体治疗转移性结直肠癌的疗效: 一项大型国际注册研究结果

2018-09-016
PREAI
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

循环肿瘤DNA分析检测微小残留病并预测II期结肠癌患者的复发

2016-07-061.1K
OAAI